Endocrine Today


The following articles appeared in the print edition of ENDOCRINE TODAY.

Table of Contents

FDA approves nonadjunctive indication for Eversense CGM

Cover Story

Microbiome’s ‘untapped extra genome’ may hold clues to prevent, treat diabetes

FDA News

FDA approves Victoza for children with type 2 diabetes

In the Journals

Adjunct therapies desired to reduce ‘constant daily burden’ of type 1 diabetes

High-activity radioiodine therapy acceptable for older adults with thyroid cancer

FRAX data suggest no increased fracture risk with aromatase inhibitor use

‘Substantial’ price increases continue for most popular brand-name drugs

Fracture risk 73% higher after Roux-en-Y gastric bypass than adjustable gastric banding

After 20-year increase, new diabetes cases decline 35%

Meeting News

Diabetes coaching sparks HbA1c progress in pediatric type 1 diabetes

D2d: Vitamin D fails to prevent type 2 diabetes

CREDENCE: Canagliflozin demonstrates CV, renal benefits in type 2 diabetes without CVD

CARMELINA, CAROLINA shed new light on CV safety for linagliptin, glimepiride

‘Medical bypass’ with triple gut-hormone infusion reduces glucose levels, body weight

Personalized bionic pancreas increases time in range vs. usual care

PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c

PREVIEW: Intensive weight loss, behavior change prevents conversion to type 2 diabetes

Teplizumab temporarily protects against type 1 diabetes in high-risk individuals


Do genes or the environment play a bigger role in the development of type 2 diabetes?